| Date | Title | Description | Source |
| 05.03.2024 | Nurix Therapeutics Announces Presentations at the American A... | - | globenewsw... |
| 08.01.2024 | Nurix Therapeutics Outlines 2024 Strategic Priorities with A... | Positive Phase 1 data presented at American Society of Hematology supports prioritizing the accelera... | einpresswi... |
| 25.10.2023 | Developer delivers 120-square-foot life science innovation h... | A new innovation hub mega campus has opened in The Woodlands.
The Alexandria Center for Advanced Tec... | houston.in... |
| 11.02.2022 | Nurix Therapeutics Announces Participation in the 11th Annua... | SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharm... | marketscre... |
| 28.01.2022 | Nurix Therapeutics : Reports Fourth Quarter and Fiscal Year ... | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corp... | marketscre... |
| 28.01.2022 | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 20... | Advanced four wholly owned and internally developed programs into clinical development
Strengthened ... | marketscre... |
| 27.01.2022 | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 20... | Advanced four wholly owned and internally developed programs into clinical development
Strengthened ... | globenewsw... |
| 10.01.2022 | Nurix Therapeutics Advances Clinical and Preclinical Pipelin... | Nurix leads protein modulation field with four active clinical stage programs
Anticipates data-rich ... | globenewsw... |
| 03.01.2022 | Nurix Therapeutics to Present at 40th Annual J.P. Morgan Hea... | SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharm... | globenewsw... |
| 12.12.2021 | Nurix Therapeutics Announces Regulatory Clearance to Initiat... | U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipa... | marketscre... |
| 12.12.2021 | Nurix Therapeutics Announces Regulatory Clearance to Initiat... | U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipa... | globenewsw... |
| 12.11.2021 | Nurix Therapeutics Announces IND clearance for DeTIL-0255, a... | Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial
Phase 1 clinical t... | marketscre... |
| 12.11.2021 | Nurix Therapeutics Announces IND clearance for DeTIL-0255, a... | Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial
Phase 1 clinical t... | globenewsw... |
| 12.11.2021 | Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhi... | DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially su... | globenewsw... |
| 12.11.2021 | Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhi... | DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially su... | marketscre... |
| 09.11.2021 | Nurix Therapeutics to Participate in Upcoming Investor Confe... | SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharm... | globenewsw... |
| 27.10.2021 | Nurix Therapeutics Announces Initial Data from the First Pha... | Robust BTK target degradation achieved in all patients treated to date
Greater than 90% degradation ... | marketscre... |
| 27.10.2021 | Nurix Therapeutics Announces Initial Data from the First Pha... | Robust BTK target degradation achieved in all patients treated to date
Greater than 90% degradation ... | globenewsw... |
| 26.10.2021 | Nurix Therapeutics to Present Initial Target Degradation Dat... | Presentation to include initial pharmacokinetic and BTK degradation data
Company to host conference ... | globenewsw... |
| 21.10.2021 | Nurix Therapeutics to Participate in the 4th Annual Targeted... | SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharm... | globenewsw... |
| 14.10.2021 | Nurix Therapeutics : Reports Third Quarter Fiscal 2021 Finan... | Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
Ex... | marketscre... |
| 14.10.2021 | Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financi... | Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
Ex... | globenewsw... |
| 21.06.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Appoi... | SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharm... | marketscre... |
| 02.06.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Prese... | Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IM... | marketscre... |
| 21.05.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Upcom... | SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharma... | marketscre... |
| 07.04.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Parti... | SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biophar... | marketscre... |
| 16.03.2021 | NURIX THERAPEUTICS, INC.
Nurix Therapeutics Announces Colla... | Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and me... | marketscre... |
| 16.03.2021 | Nurix Therapeutics Announces Collaboration for the Discovery... | Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and me... | globenewsw... |
| 09.03.2021 | Nurix Therapeutics to Participate and Present at Upcoming In... | SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biophar... | globenewsw... |
